Literature DB >> 4713345

Cyproterone acetate in the treatment of advanced carcinoma of the prostate.

R B Smith, P C Walsh, W E Goodwin.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1973        PMID： 4713345     DOI： 10.1016/s0022-5347(17)60128-9

Source DB:  PubMed          Journal:  J Urol        ISSN： 0022-5347            Impact factor:   7.450


× No keyword cloud information.
  8 in total

Review 1.  Pharmacology and clinical use of antiandrogens: a short review.

Authors:  F Neumann
Journal:  Ir J Med Sci       Date:  1982-03       Impact factor: 1.568

2.  3H-cyproterone acetate: binding characteristics to human uterine progestagen receptors.

Authors:  H J Grill; B Manz; W Elger; K Pollow
Journal:  J Endocrinol Invest       Date:  1985-04       Impact factor: 4.256

Review 3.  Hormonal therapy for stage D cancer of the prostate.

Authors:  M R Gudziak; A Y Smith
Journal:  West J Med       Date:  1994-04

Review 4.  Cyproterone. A review of its pharmacology and therapeutic efficacy in prostate cancer.

Authors:  L B Barradell; D Faulds
Journal:  Drugs Aging       Date:  1994-07       Impact factor: 3.923

5.  Gestagens in the management of prostatic carcinoma.

Authors:  Z Szendröi
Journal:  Int Urol Nephrol       Date:  1984       Impact factor: 2.370

6.  5-Fluorouracil (5-Fu) in the treatment of prostatic hyperplasia.

Authors:  X Y Wei; X M Zhou
Journal:  Urol Res       Date:  1987

7.  A possible explanation for the peripheral selectivity of a novel non-steroidal pure antiandrogen, Casodex (ICI 176,334).

Authors:  S N Freeman; W I Mainwaring; B J Furr
Journal:  Br J Cancer       Date:  1989-11       Impact factor: 7.640

8.  Androgen receptor variants: another twist in the plot.

Authors:  Jill A Macoska
Journal:  Oncotarget       Date:  2017-03-07
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.